Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.17 USD
Change Today +0.08 / 1.31%
Volume 9.1K
HSGX On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter S. Greenleaf

AgeTotal Calculated CompensationThis person is connected to 105 board members in 2 different organizations across 7 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Peter S. Greenleaf has been the Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since March 03, 2014. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. Mr. Greenleaf served as President of MedImmune, LLC (also known as MedImmune, Inc.). Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, ...

Read Full Background

Corporate Headquarters*

830 Winter Street
Waltham, Massachusetts 02451

United States

Phone: 781-547-7900
Fax: 781-547-4452

Board Members Memberships*

Chief Executive Officer and Director


Saint Joseph's University
Western Connecticut State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$440,192

Stock Options*

All Other Compensation$2,025
Unexercisable Options1,000,000
Unexercisable Options Value$6,656,000
Total Value of Options$6,656,000
Total Number of Options1,000,000

Total Compensation*

Total Annual Cash Compensation$811,979
Total Short Term Compensation$440,192
Other Long Term Compensation$2,025
Total Calculated Compensation$5,650,759
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSGX:US $6.17 USD +0.08


Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HISTOGENICS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at